diphenylamine has been researched along with Pancreatic Neoplasms in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Beijnen, JH; Bernards, R; de Vos, FYFL; Devriese, LA; Eskens, FALM; Huijberts, SCFA; Huitema, ADR; Lolkema, MPJK; Marchetti, S; Monkhorst, K; Opdam, FL; Rosing, H; Schellens, JHM; Steeghs, N; Thijssen, B; van Brummelen, EMJ; van Geel, RMJM | 1 |
| Beer, AJ; Braren, R; Esposito, I; Fingerle, A; Gupta, A; Heid, I; Sengkwawoh-Lueong, S; Siveke, JT; Steiger, K; Teichmann, N; Trajkovic-Arsic, M; Wenzel, P; Wörner, C | 1 |
| Burmi, RS; Gabra, H; Maginn, EN; Stronach, EA; Wasan, HS | 1 |
| Byrne, FL; Counter, CM; Hoehn, KL; Kashatus, DF; Kashatus, JA; Myers, LJ; Nascimento, A; Sher, A | 1 |
| Bridgewater, J; Cascinu, S; Childs, BH; Dueland, S; Garosi, VL; Giurescu, M; Haas, M; Jassem, J; Martens, UM; Melichar, B; Michl, P; Peeters, M; Rajagopalan, P; Riess, H; Ross, P; Roth, K; Saramak, P; Schmiegel, W; Schulz, A; Seidel, H; Teufel, M; Van Brummelen, D; Van Laethem, JL; Weekes, C; Zaniboni, A | 1 |
| Halilovic, E; Pagliarini, R; Rosen, N; Sellers, WR; She, QB; Solit, DB; Ye, Q | 1 |
| Chang, Q; Chapman, MS; Hedley, DW; Miner, JN | 1 |
| Flecha, AR; Galbán, CJ; Galbán, S; Karnak, D; Keller, P; Lawrence, TS; Ram, A; Rehemtulla, A; Ross, BD; Sebolt-Leopold, J; Williams, TM | 1 |
2 trial(s) available for diphenylamine and Pancreatic Neoplasms
| Article | Year |
|---|---|
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Diphenylamine; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasms; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Quinazolinones | 2020 |
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Diphenylamine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Sulfonamides; Treatment Outcome | 2017 |
6 other study(ies) available for diphenylamine and Pancreatic Neoplasms
| Article | Year |
|---|---|
Apparent Diffusion Coefficient (ADC) predicts therapy response in pancreatic ductal adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Diffusion Magnetic Resonance Imaging; Diphenylamine; Disease Models, Animal; Humans; Image Processing, Computer-Assisted; MAP Kinase Kinase Kinases; Mice; Neoadjuvant Therapy; Pancreatic Neoplasms; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors; Sulfonamides | 2017 |
Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bcl-2-Like Protein 11; Benzamides; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Diphenylamine; Drug Screening Assays, Antitumor; Humans; MAP Kinase Signaling System; Morpholines; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); RNA, Small Interfering; TOR Serine-Threonine Kinases; Triazines | 2019 |
Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth.
Topics: Animals; Benzamides; Cell Line, Tumor; Diphenylamine; Dynamins; Gene Knockdown Techniques; GTP Phosphohydrolases; HEK293 Cells; HeLa Cells; Humans; Mice; Mice, Nude; Microtubule-Associated Proteins; Mitochondrial Dynamics; Mitochondrial Proteins; Mitogen-Activated Protein Kinase 1; Neoplasms, Experimental; Pancreatic Neoplasms; Phosphorylation; ras Proteins; Serine | 2015 |
PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
Topics: Alleles; Animals; Benzamides; Cell Growth Processes; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Colonic Neoplasms; Cyclin D1; Diphenylamine; Extracellular Signal-Regulated MAP Kinases; Gene Knockout Techniques; HCT116 Cells; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Mutation; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); ras Proteins | 2010 |
Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts.
Topics: Animals; Antineoplastic Agents; Bromodeoxyuridine; Cell Cycle; Cell Line, Tumor; Diphenylamine; Enzyme Inhibitors; Humans; Male; MAP Kinase Kinase Kinases; Mice; Neoplasm Transplantation; Pancreatic Neoplasms; Signal Transduction; Sirolimus; Sulfonamides | 2010 |
Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer.
Topics: Animals; Apoptosis; Benzamides; Cell Line, Tumor; Chlorpropamide; Combined Modality Therapy; Diphenylamine; Enzyme Activation; Enzyme Inhibitors; Female; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Radiation-Sensitizing Agents; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |